Patent Leaderboard
USPTO Patent Rankings Data through Dec 31, 2025
Home › Combination therapy comprising an FGFR inhibitor and a Nectin-4 targeting agent

Combination therapy comprising an FGFR inhibitor and a Nectin-4 targeting agent

US Patent 12065494 · Granted Aug 20, 2024

Estimated economic value: $80,648,000 ⓘ

Assignee

Inventors

View full patent text on Google Patents →

More Patents by These Inventors

Combination therapy comprising AXL/MER and PD-1/PD-L1 inhibitors2025
Low dose combination therapy for treatment of myeloproliferative neoplasms2022
Low dose combination therapy for treatment of myeloproliferative neoplasms2020
Methods and compositions for enhancing the immunostimulatory effect of interleuk2002